Nothing that mattered this week turned on whether a device works. Boston Scientific’s quarter was dented by an intrusion on its own network, Medline is pulling or repairing every bed it has shipped over wiring and bed rails, and a hospital system paid $5.7 billion for the places surgery actually happens. Cooper Companies’ CEO, for his part, was out effective immediately, weeks after an activist investor suggested the company sell most of itself.
Put your brand in front of 28,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 💰 Boston Scientific cuts its year for the third time, and a hack did $150 million of it
Q3 revenue was $5.14 billion, up 1.5 percent, with net income of $582 million against $755 million a year earlier. Full-year growth guidance drops to 4.25 percent from 5.5 to 6.5 percent, and about $150 million of the miss traces to a third-quarter cyberattack. The $14.5 billion Penumbra close slides to early Q1 2027. The pattern worth watching is not the cut but its cause: an operational failure, not a market one, and the third revision in a year erodes the premium a serial compounder trades on.
MedTech Dive
2.⚠️ Medline is pulling or fixing every bed it makes
FDA’s October 29 early alert covers every Medline brand bed and component, including pendants, control boxes, actuators, rails and accessories. The hazards are electrical overheating that can start a fire, and entrapment or asphyxiation from rails and pendants. As of October 20, Medline had reported two deaths and 16 serious injuries. FDA’s interim advice is to keep beds unplugged except while repositioning a patient. Repair, replacement or refund reaches only units bought in the last five years, which leaves the installed base in long-term care doing the math.
FDA
3. 🏥 A health system paid $5.7 billion for the places surgery actually happens
HealthSpan Partners, an affiliate of Bon Secours Mercy Health, agreed on October 26 to buy Surgery Partners for $5.7 billion including debt, at $23.50 a share in cash. Bain, which holds about 39 percent, rolls its stake into the new entity. It is the second time a health system has bought a national ASC operator outright, after Ascension and Amsurg. For device companies, the buyer at the ambulatory surgery center is consolidating into a system contract, and the pricing conversation moves with it.
Becker’s ASC Review
🧰 Your best engineer shouldn’t be building the investor deck.
Device teams are staffed for engineering, regulatory, and quality. The commercial case is a different job: positioning, the investor and sales materials, the website, the story a buyer actually hears. It lands on whoever has room that week, or gets split across vendors who never speak to each other. RŌG Health builds the whole set as one group, with specialists on the parts that need them. We were Scientia Vascular’s strategic and creative partner for five years, right up to the end; Scientia was acquired by Medtronic this year for $550 million. Start with a conversation about where your case is thin.
Sponsored by RŌG Health
4. 🪑 Cooper’s CEO is out, effective immediately
Albert White left the president and CEO roles at Cooper Companies with no transition period, staying on as a strategic adviser through April 1. Walter Rosebrough Jr., Steris’s chief executive from 2007 to 2021, becomes executive chair and takes day-to-day oversight while a search runs. Jana Partners had pushed in September for Cooper to shop its fertility and device assets and find a buyer for CooperVision. Three directors will not stand again in 2027. Guidance held at 2 to 3 percent organic growth, which is the problem.
MedTech Dive
5. 📋 FDA wants your IDE in eSTAR, and says it will read it in 30 days
Draft guidance issued October 27 would move investigational device exemption applications to the eSTAR template at CDRH and CBER, mandatory after a transition of at least a year once final. FDA says it plans to review electronic IDEs within 30 days and does not intend to grant waivers, since the existing format is free. Comments close December 28 on docket FDA-2026-D-11188. eSTAR already gates every 510(k) and De Novo, so the real news is the review-clock commitment attached to it.
Regulatory Focus / RAPS
6. 🏭 Bracco is spending $230 million on its first US plant
The Italian imaging company will build a sterile manufacturing site in Sanford, North Carolina, for injectable contrast media across CT, MRI and contrast-enhanced ultrasound, with about 200 jobs. North Carolina’s Economic Investment Committee approved a job development investment grant on October 27, worth up to roughly $2.86 million in reimbursement over 12 years. CEO Fulvio Renoldi Bracco called the US the company’s largest market. Contrast agents are the quiet single-source risk in imaging departments, and the onshoring logic here is supply, not tariff math.
Medical Device Network
7. 🧠 A 105-day 510(k) for neurovascular CT
FDA cleared Deep Reasoning AI’s NeuroDR under 510(k) K262134, AI software for neurovascular CT angiography that runs automatically once a scan completes. The company says clearance came 105 days after submission, with regulatory work by Innolitics and performance studies by 3DR Labs. That turnaround is the number to file away: a small company with outsourced regulatory and testing cleared far inside the usual window, which says more about submission quality than about any change at the agency.
Medical Device Network
8. 🤝 Profound hands US distribution to Cook and keeps the disposables
Toronto-based Profound Medical signed a supply and distribution agreement with Cook Medical’s interventional MRI division for its TULSA-Pro prostate ablation system. Cook buys systems at a set transfer price and sells them through its Copernicus bundling program, while customers buy single-use disposables and service contracts directly from Profound. Profound’s own reps keep selling to sites with compatible scanners. It is the structure to study if you have a capital device and no field force: give away the box, keep the annuity.
AuntMinnie
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
The Pathway publishes original reporting and analysis on the medical device and medtech industry, as well as curated summaries of publicly available industry news. Each summary links to the original report, which remains the authoritative account; the read that follows it is The Pathway’s own analysis, not the view of the cited outlet. Where third-party content is referenced or linked, it remains the property of its respective authors and publishers, and The Pathway claims no ownership of external content.
All content is provided for informational purposes only and should not be relied upon as medical, regulatory, legal, or investment advice. Readers should consult original sources and qualified professionals where appropriate.
Some issues include sponsored or partner content, which is always labeled. Sponsorship does not influence the selection of third-party news items or how they are characterized.
We correct errors. Send them to update@thepathway.email